Page last updated: 2024-08-26
equol and B16 Melanoma
equol has been researched along with B16 Melanoma in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kamachi, S; Komatsu, S; Kumazoe, M; Lin, I; Murata, M; Oka, C; Tachibana, H; Yamashita, S | 1 |
Other Studies
1 other study(ies) available for equol and B16 Melanoma
| Article | Year |
|---|---|
Soy isoflavone metabolite equol inhibits cancer cell proliferation in a PAP associated domain containing 5-dependent and an estrogen receptor-independent manner.
Topics: Cell Line, Tumor; Cell Proliferation; Equol; Estrogen Receptor alpha; HeLa Cells; Humans; Isoflavones; MCF-7 Cells; Melanoma, Experimental; MicroRNAs; Neoplasm Transplantation; Receptors, Estrogen; RNA Nucleotidyltransferases; RNA, Small Nucleolar | 2022 |